Mindfulness and Tai Chi for Cancer Health (MATCH) Study: Primary Outcomes of a Preference-Based Multisite Randomized Comparative Effectiveness Trial [0.03%]
癌症患者偏好基于 mindfulness 和太极的多中心随机对照效果研究的主要结果：MATCH 研究
Linda E Carlson,Jennifer M Jones,Devesh Oberoi et al.
Linda E Carlson et al.
Purpose: Many cancer survivors have high levels of distress and psychosocial symptoms. Two mind-body interventions for treating these problems are Mindfulness-Based Cancer Recovery (MBCR) and Tai Chi/Qigong (TCQ). However...
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML [0.03%]
用于新诊断的NPM1突变或KMT2A重排AML患者的阿扎胞苷、维奈克拉和瑞武门必布olina治疗
Joshua F Zeidner,Tara L Lin,Rina Li Welkie et al.
Joshua F Zeidner et al.
Purpose: Azacitidine and venetoclax is a standard frontline treatment regimen for newly diagnosed older adults with AML; however, long-term outcomes remain poor. Revumenib is an oral menin inhibitor with clinical activity...
Long-Term Follow-Up of E3311, an ECOG-ACRIN Cancer Research Group Phase II Trial of Transoral Surgery and Risk-Based Adjuvant Treatment in Human Papillomavirus-Initiated Oropharynx Cancer [0.03%]
一项关于通过经口手术联合基于风险的辅助治疗的人乳头瘤病毒感染相关性喉癌患者的长期随访研究（E3311）：ECOG-ACRIN癌症研究组II期临床试验结果
Barbara Burtness,Yael Flamand,Harry Quon et al.
Barbara Burtness et al.
This phase II trial of transoral surgery (TOS) with deintensified postoperative management in human papillomavirus (HPV)-associated oropharynx cancer (OPC) enrolled patients with resectable cT1-2 stage III/IV American Joint Committee on Can...
International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma [0.03%]
国际骨髓瘤学会/国际骨髓瘤工作组关于高危多发性骨髓瘤定义共识建议
Hervé Avet-Loiseau,Faith E Davies,Mehmet K Samur et al.
Hervé Avet-Loiseau et al.
Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based o...
Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor-Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) [0.03%]
共价布鲁顿酪氨酸激酶抑制剂经治的慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的III期PIRT试验：Pirtobrutinib与Idelalisib/Rituximab或Bendamustine/Rituximab对比（BRUIN CLL-321）
Jeff P Sharman,Talha Munir,Sebastian Grosicki et al.
Jeff P Sharman et al.
Purpose: Pirtobrutinib, a noncovalent, Bruton tyrosine kinase inhibitor (BTKi), has shown clinical efficacy and a favorable safety profile. BRUIN CLL-321 was an open-label, randomized phase III study conducted exclusively...
Novel Systemic Anticancer Treatments and Health Services Use at the End of Life Among Adults With Cancer [0.03%]
癌症成人新型全身抗癌治疗及其临终阶段的卫生服务利用率
Javaid Iqbal,Rahim Moineddin,Kieran L Quinn et al.
Javaid Iqbal et al.
Purpose: Use of chemotherapy at the end of life (EOL) is discouraged, but evidence to guide decisions on the use of novel systemic anticancer treatment (SACT) agents is lacking. We examined trends of use among SACT types ...
Long-term follow-up of real-world adjuvant anti-PD1 checkpoint inhibition and targeted therapy in stage III melanoma patients [0.03%]
III期黑色素瘤患者的长期随访：真实世界的抗PD1检查点抑制和靶向治疗效果
Georg C Lodde,Jessica C Hassel,Imke von Wasielewski et al.
Georg C Lodde et al.
Purpose: Adjuvant treatment with immune checkpoint inhibition (PD1) and targeted therapy (TT) with BRAF+MEK inhibitors significantly improved recurrence-free survival (RFS) of stage III melanoma patients. We investigated ...
Isatuximab Subcutaneous by On-Body Delivery System vs Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 IRAKLIA Study [0.03%]
皮下注射联合体内输送系统给药的伊沙妥昔单抗与静脉输注伊沙妥昔单抗联合泊马西利和地塞米松治疗复发或难治多发性骨髓瘤：IRAKLIA III期研究
Sikander Ailawadhi,Ivan Špička,Andrew Spencer et al.
Sikander Ailawadhi et al.
Purpose: To report results of the multicenter, open-label IRAKLIA trial (NCT05405166) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (...
Long-Term (≥5-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed/Refractory Multiple Myeloma [0.03%]
CILTACABTAGENE AUTOLEUCEL治疗复发和难治多发性骨髓瘤患者后长期（≥5年）缓解和生存：CARTITUDE-1研究者的报告
Sundar Jagannath,Thomas G Martin,Yi Lin et al.
Sundar Jagannath et al.
CARTITUDE-1 evaluated ciltacabtagene autoleucel (cilta-cel) in patients with heavily pretreated relapsed/refractory multiple myeloma (RRMM). We describe overall survival (OS), ≥5-year progression-free outcomes, associated biomarkers, and s...